{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T23:25:16Z","timestamp":1777418716621,"version":"3.51.4"},"reference-count":48,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2020,5,15]],"date-time":"2020-05-15T00:00:00Z","timestamp":1589500800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01CA204167"],"award-info":[{"award-number":["R01CA204167"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U01CA221046"],"award-info":[{"award-number":["U01CA221046"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01CA240963"],"award-info":[{"award-number":["R01CA240963"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>High expression levels of the tumor-associated antigen MUC1 have been correlated with tumor aggressiveness, poor response to therapy, and poor survival in several tumor types, including breast, pancreatic, and epithelial ovarian cancer. Herein, we report the synthesis, characterization, and in vivo evaluation of a novel radioimmunoconjugate for the immuno-positron emission tomography (immunoPET) imaging of MUC1 expression based on the AR20.5 antibody. To this end, we modified AR20.5 with the chelator desferrioxamine (DFO) and labeled it with the positron-emitting radiometal zirconium-89 (t1\/2 ~3.3 d) to produce [89Zr]Zr-DFO-AR20.5. In subsequent in vivo experiments in athymic nude mice bearing subcutaneous MUC1-expressing ovarian cancer xenografts, [89Zr]Zr-DFO-AR20.5 clearly delineated tumor tissue, producing a tumoral activity concentration of 19.1 \u00b1 6.4 percent injected dose per gram (%ID\/g) at 120 h post-injection and a tumor-to-muscle activity concentration ratio of 42.4 \u00b1 10.6 at the same time point. Additional PET imaging experiments in mice bearing orthotopic MUC1-expressing ovarian cancer xenografts likewise demonstrated that [89Zr]Zr-DFO-AR20.5 enables the visualization of tumor tissue\u2014including metastatic lesions\u2014with promising tumor-to-background contrast.<\/jats:p>","DOI":"10.3390\/molecules25102315","type":"journal-article","created":{"date-parts":[[2020,5,18]],"date-time":"2020-05-18T11:34:14Z","timestamp":1589801654000},"page":"2315","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["89Zr-Labeled AR20.5: A MUC1-Targeting ImmunoPET Probe"],"prefix":"10.3390","volume":"25","author":[{"given":"Kimberly","family":"Fung","sequence":"first","affiliation":[{"name":"Department of Chemistry, Hunter College, City University of New York, New York, NY 10021, USA"},{"name":"Ph.D. Program in Chemistry, The Graduate Center of the City University of New York, New York, NY 10016, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Delphine","family":"Vivier","sequence":"additional","affiliation":[{"name":"Department of Chemistry, Hunter College, City University of New York, New York, NY 10021, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3939-6706","authenticated-orcid":false,"given":"Outi","family":"Kein\u00e4nen","sequence":"additional","affiliation":[{"name":"Department of Chemistry, Hunter College, City University of New York, New York, NY 10021, USA"},{"name":"Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elaheh Khozeimeh","family":"Sarbisheh","sequence":"additional","affiliation":[{"name":"Department of Chemistry, University of Saskatchewan, Saskatoon, SK S7N 5B5, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8619-1199","authenticated-orcid":false,"given":"Eric W.","family":"Price","sequence":"additional","affiliation":[{"name":"Department of Chemistry, University of Saskatchewan, Saskatoon, SK S7N 5B5, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian M.","family":"Zeglis","sequence":"additional","affiliation":[{"name":"Department of Chemistry, Hunter College, City University of New York, New York, NY 10021, USA"},{"name":"Ph.D. Program in Chemistry, The Graduate Center of the City University of New York, New York, NY 10016, USA"},{"name":"Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA"},{"name":"Department of Radiology, Weill Cornell Medical College, New York, NY 10021, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2020,5,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"15286","DOI":"10.1016\/S0021-9258(18)77254-2","article-title":"Molecular cloning and expression of human tumor-associated polymorphic epithelial mucin","volume":"265","author":"Gendler","year":"1990","journal-title":"J. Biol. Chem."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/j.1600-065X.1995.tb00077.x","article-title":"MUC-1 epithelial tumor mucin-based immunity and cancer vaccines","volume":"145","author":"Finn","year":"1995","journal-title":"Immunol. Rev."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1093\/annonc\/mdh472","article-title":"Phase I trial of a murine antibody to MUC1 in patients with metastatic cancer: Evidence for the activation of humoral and cellular antitumor immunity","volume":"15","author":"Rha","year":"2004","journal-title":"Ann. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0925-4439(99)00055-1","article-title":"MUC1 and cancer","volume":"1455","author":"Burchell","year":"1999","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1023\/A:1011379725811","article-title":"MUC1, the renaissance molecule","volume":"6","author":"Gendler","year":"2001","journal-title":"J. Mammary Gland Biol. Neoplasia"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/(SICI)1096-9896(199711)183:3<311::AID-PATH917>3.0.CO;2-2","article-title":"Expression of MUC1 and MUC2 mucins in epithelial ovarian tumors","volume":"183","author":"Dong","year":"1997","journal-title":"J. Pathol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.ygyno.2007.02.004","article-title":"Expression of MUC1 in primary and metastatic human epithelial ovarian cancer and its therapeutic significance","volume":"105","author":"Wang","year":"2007","journal-title":"Gynecol. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1111\/j.1365-2559.2010.03667.x","article-title":"Expression of aberrantly glycosylated Mucin-1 in ovarian cancer","volume":"57","author":"Frings","year":"2010","journal-title":"Histopathology"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1089\/15368590152740716","article-title":"Characterization of an anti-MUC1 monoclonal antibody with potential as a cancer vaccine","volume":"20","author":"Qi","year":"2001","journal-title":"Hybrid. Hybridomics"},{"key":"ref_10","first-page":"187","article-title":"MUC1 and metastatic cancer: Expression, function, and therapeutic targeting","volume":"7","author":"Horm","year":"2013","journal-title":"Cell Adhes. Commun."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21551","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J. Clin."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1007\/s00262-011-1010-x","article-title":"Soluble MUC1 and serum MUC1-specific antibodies are potential prognostic biomarkers for platinum-resistance ovarian cancer","volume":"60","author":"Budiu","year":"2011","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s10555-013-9423-y","article-title":"The role of tumour-associated MUC1 in epithelial ovarian cancer metastasis and progression","volume":"32","author":"Deng","year":"2013","journal-title":"Cancer Metastasis Rev."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1158\/1078-0432.CCR-08-1745","article-title":"Intracellular MUC1 peptides inhibit cancer progression","volume":"15","author":"Bitler","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"99","DOI":"10.2174\/157489210790936252","article-title":"Anti-cancer therapies that utilize cell penetrating peptides","volume":"5","author":"Bitler","year":"2010","journal-title":"Recent Pat. Anti-Cancer Drug Discov."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.bbrc.2011.01.029","article-title":"Anti-MUC1 antibody inhibits EGF receptor signaling in cancer cells","volume":"405","author":"Hisatsune","year":"2011","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1002\/ijc.23725","article-title":"Induction of IgG antibodies to MUC1 and survival in patients with epithelial ovarian cancer","volume":"123","author":"Oei","year":"2008","journal-title":"Int. J. Cancer"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"R27","DOI":"10.1186\/bcr1505","article-title":"Pilot phase III immunotherapy study in early-stage breast cancer patients using oxidized mannan-MUC1","volume":"8","author":"Apostolopoulos","year":"2006","journal-title":"Breast Cancer Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.immuni.2016.10.014","article-title":"Targeting of tumor-associated glycoforms of MUC1 with CAR T cells","volume":"45","author":"Maher","year":"2016","journal-title":"Immunity"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"76","DOI":"10.4161\/cbt.7.1.5132","article-title":"Bismuth-213 radioimmunotherapy with C595 anti-MUC1 monoclonal antibody in an ovarian cancer ascites model","volume":"7","author":"Song","year":"2008","journal-title":"Cancer Biol. Therapy"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.nucmedbio.2011.02.009","article-title":"Preparation and biological evaluation of 177Lu conjugation PR81 for radioimmunotherapy of breast cancer","volume":"38","author":"Salouti","year":"2011","journal-title":"Nucl. Med. Biol."},{"key":"ref_22","first-page":"439","article-title":"Preclinical evaluation of copper-67 labelled anti-MUC1 mucin antibody C595 for therapeutic use in bladder cancer","volume":"24","author":"Hughes","year":"1997","journal-title":"Eur. J. Nucl. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1002\/ijc.20004","article-title":"Combined 90yttrium-DOTA-labeled PAM4 antibody radioimmunotherapy and gemcitabine radiosensitization for the treatment of a human pancreatic cancer xenograft","volume":"109","author":"Gold","year":"2004","journal-title":"Int. J. Cancer"},{"key":"ref_24","first-page":"1","article-title":"Update on Mucin-1 immunotherapy in cancer: A clinical perspective","volume":"25","author":"Rivalland","year":"2015","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_25","first-page":"773","article-title":"MUC1 in cancer immunotherapy: New hope or phantom menace?","volume":"84","author":"Syrkina","year":"2019","journal-title":"Biochemistry"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1042\/BST20170400","article-title":"Latest developments in MUC1 immunotherapy","volume":"46","author":"Burchell","year":"2018","journal-title":"Biochem. Soc. Trans."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.nucmedbio.2012.08.004","article-title":"PET imaging with 89Zr: From radiochemistry to the clinic","volume":"40","author":"Deri","year":"2013","journal-title":"Nucl. Med. Biol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1021\/acs.bioconjchem.7b00325","article-title":"89Zr-immuno-positron emission tomography in oncology: State-of-the-art 89Zr radiochemistry","volume":"28","author":"Heskamp","year":"2017","journal-title":"Bioconj. Chem."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1536012118801223","article-title":"Application of immuno-PET in antibody-drug conjugate development","volume":"17","author":"Carmon","year":"2018","journal-title":"Mol. Imaging"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"900","DOI":"10.2967\/jnumed.117.202010","article-title":"First-in-human human epidermal growth factor receptor 2-targeted imaging using 89Zr-pertuzumab PET\/CT: Dosimetry and clinical application in patients with breast cancer","volume":"59","author":"Ulaner","year":"2018","journal-title":"J. Nucl. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/jlcr.3605","article-title":"89Zr-immunoPET companion diagnostics and their impact in clinical drug development","volume":"61","author":"McKnight","year":"2018","journal-title":"J. Label. Compd. Radiopharm."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.molmed.2014.02.007","article-title":"MUC1: A multifaceted oncoprotein with a key role in cancer progression","volume":"20","author":"Nath","year":"2014","journal-title":"Trends Mol. Med."},{"key":"ref_33","first-page":"677","article-title":"Glycosylation of MUC1 influences the binding of a therapeutic antibody by altering the conformational equilibrium of the antigen","volume":"27","author":"Movahedin","year":"2017","journal-title":"Glycobiology"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s00262-017-2095-7","article-title":"Combination of mAb-AR20.5, anti-PD-L1 and PolyICLC inhibits tumor progression and prolongs survival of MUC1.Tg mice challenged with pancreatic tumors","volume":"67","author":"Mehla","year":"2018","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"284","DOI":"10.3322\/caac.21456","article-title":"Ovarian cancer statistics, 2018","volume":"68","author":"Torre","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.nucmedbio.2015.07.012","article-title":"Development of [64Cu]-DOTA-PR81 radioimmunoconjugate for MUC-1 positive PET imaging","volume":"43","author":"Alirezapour","year":"2016","journal-title":"Nucl. Med. Biol."},{"key":"ref_37","first-page":"4663","article-title":"Concurrent radiotherapy and tumor targeting with 111In-HMFG1-F(ab\u2019)2 in patients with MUC1-positive non-small cell lung cancer","volume":"25","author":"Garkavij","year":"2005","journal-title":"Anticancer Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0001-2998(99)80028-2","article-title":"Breast cancer imaging with radiolabeled antibodies","volume":"39","author":"Goldenberg","year":"1999","journal-title":"Semin. Nucl. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"158","DOI":"10.2967\/jnumed.107.046185","article-title":"Multifunctional antibodies by the dock-and-lock method for improved cancer imaging and therapy by pretargeting","volume":"49","author":"Goldenberg","year":"2008","journal-title":"J. Nucl. Med."},{"key":"ref_40","first-page":"3712","article-title":"Immunoscintigraphy with positron emission tomography: Gallium-68 chelate imaging of breast cancer pretargeted with bispecific anti-MUC1\/anti-Ga chelate antibodies","volume":"61","author":"Schuhmacher","year":"2001","journal-title":"Cancer Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.7150\/ijms.35452","article-title":"Evaluation of a novel monoclonal antibody against tumor-associated MUC1 for diagnosis and prognosis of breast cancer","volume":"16","author":"Stergiou","year":"2019","journal-title":"Int. J. Med. Sci."},{"key":"ref_42","first-page":"52521","article-title":"The bioconjugation and radiosynthesis of 89Zr-DFO-labeled antibodies","volume":"96","author":"Zeglis","year":"2015","journal-title":"J. Vis. Exp."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.nucmedbio.2009.05.007","article-title":"Standardized methods for the production of high specific-activity zirconium-89","volume":"36","author":"Holland","year":"2009","journal-title":"Nucl. Med. Biol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"771","DOI":"10.2967\/jnumed.115.167072","article-title":"Preclinical 89Zr immuno-PET of high-grade serous ovarian cancer and lymph node metastasis","volume":"57","author":"Sharma","year":"2016","journal-title":"J. Nucl. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"7014","DOI":"10.1158\/1078-0432.CCR-18-3667","article-title":"Retooling a blood-based biomarker: Phase I assessment of the high-affinity CA19-9 antibody HuMab-5B1 for immunoPET","volume":"25","author":"Lohrmann","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"15850","DOI":"10.1073\/pnas.1506542112","article-title":"Site-specifically labeled CA19.9-labeled immunoconjugate for the PET, NIRF, and multimodal PET\/NIRF imaging of pancreatic cancer","volume":"112","author":"Houghton","year":"2015","journal-title":"PNAS"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.2967\/jnumed.118.223636","article-title":"The impact of Fc[gamma]RI binding on immunoPET","volume":"60","author":"Vivier","year":"2019","journal-title":"J. Nucl. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.7150\/thno.39089","article-title":"The influence of glycans-specific bioconjugation on the Fc[gamma]RI binding and in vivo performance of 89Zr-DFO-pertuzumab","volume":"10","author":"Vivier","year":"2020","journal-title":"Theranostics"}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/25\/10\/2315\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:28:58Z","timestamp":1760174938000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/25\/10\/2315"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,15]]},"references-count":48,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2020,5]]}},"alternative-id":["molecules25102315"],"URL":"https:\/\/doi.org\/10.3390\/molecules25102315","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,15]]}}}